This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alnylam's (ALNY) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2017.
Zoetis (ZTS) Warming Up to Q4 Earnings: What's in Store?
by Zacks Equity Research
Zoetis (ZTS) is working on returning value to shareholders in the form of share buybacks and dividends.
Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
Although Prothena's (PRTA) track record is good, the company is unlikely to beat estimates in the current quarter given the unfavorable rank and Earnings ESP.
Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow
by Zacks Equity Research
Regeneron (REGN) fourth-quarter results were encouraging as the company topped both earnings and sales estimates on the back of Eylea sales.
Theravance, J&J Ink Deal for Inflammatory Intestinal Drug
by Zacks Equity Research
Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.
Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4
by Zacks Equity Research
Alexion (ALXN) surpass earnings and sales estimates in the fourth quarter of 2017. The company received FDA approval for label expansion of Soliris in the United States.
Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down
by Zacks Equity Research
Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.
Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural
by Zacks Equity Research
Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural
5 Biotech Stocks Set to Trump Estimates This Earnings Season
by Zacks Equity Research
Total earnings for the medical sector are up 16.9% from the same period last year on 8.5% higher revenues so far.
Bristol-Myers' Opdivo/Yervoy Combo Positive in Cancer Study
by Zacks Equity Research
Bristol-Myers' (BMY) blockbuster drug, Opdivo, in combination with Yervoy, proves its worth again by demonstrating superiority in a lung cancer study.
Spectrum Pharma's Rolontis Positive in Pivotal Cancer Study
by Zacks Equity Research
Spectrum Pharmaceuticals' (SPPI) Rolontis meets primary endpoint in a phase III study for management of neutropenia in early stage breast cancer.
Pfizer Files for Xtandi in Early Stage Prostate Cancer
by Zacks Equity Research
Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.
Roche Reports Positive Data From Tecentriq-Avastin Study
by Zacks Equity Research
Roche reported positive results from a phase III study on the combination of immunotherapy drug Tecentriq and oncology drug Avastin.
5 of the Best Efficient Stocks for Your Portfolio
by Tirthankar Chakraborty
Companies with a favorable efficiency level are expected to provide impressive returns as efficiency is believed to be positively correlated with price performance.
Is a Beat in the Cards for ImmunoGen (IMGN) in Q4 Earnings?
by Zacks Equity Research
ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q4.
Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?
by Zacks Equity Research
Keryx (KERX) will provide updates on lead drug Auryxia when it reports Q4 results on Feb 7.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Alexion's (ALXN) Q4 results are likely to driven by Soliris' performance.
Strength Seen in Alkermes (ALKS): Stock Soars 8.7%
by Zacks Equity Research
Alkermes (ALKS) was a big mover last session, as the company saw its shares rise more than 8% on Friday amid huge volumes.
Allergan's Anti-Infective Drug Avycaz Receives Third FDA Nod
by Zacks Equity Research
The FDA's label expansion approval for Allergan's (AGN) Avycaz marks its third therapeutic indication nod for the anti-infective drug in the United States.
Puma, CANbridge Team Up to Commercialize Nerlynx in China
by Zacks Equity Research
Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.
Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review
by Zacks Equity Research
Alnylam's NDA for lead candidate patisiran is accepted by the FDA and granted priority review. The FDA also set an action date of Aug 11, 2018.
Is a Beat in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might lead the company to an earnings beat in Q4.
Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?
by Zacks Equity Research
Gilead's HCV franchise is under significant pressure due to increasing competition and the decline in franchise sales is expected to impact fourth-quarter results.
Roche (RHHBY) Posts Solid 2017 Sales on Tecentriq & Alecensa
by Zacks Equity Research
Roche reported strong sales for 2017 buoyed by performance of new drugs ??? Tecentriq, Alecensa and Perjeta which offset the decline in Tarceva and Avastin.
Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat
by Zacks Equity Research
Novo Nordisk's (NVO) top-line growth was backed by growth in new-generation insulin, Victoza, Saxenda, and haemophilia products.